Medical
Health
Therapy

BioTime

$1.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BioTime and other stocks, options, ETFs, and crypto commission-free!

About

BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Read More Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Employees
79
Headquarters
Alameda, California
Founded
1990
Market Cap
185.62M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
620.77K
High Today
$1.48
Low Today
$1.43
Open Price
$1.46
Volume
144.19K
52 Week High
$2.81
52 Week Low
$0.66

Collections

Medical
Health
Therapy
Cancer Prevention
Research And Development
Technology

News

Markets InsiderMar 18

BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 20th, 2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the Track 2 Room in New York, NY. Interested parties can access a live audio webcast on the Events and Presentations section of BioTime’s website and an archived present...

538
Seeking AlphaMar 14

BioTime, Inc. (BTX) CEO Brian Culley on Q4 2018 Results - Earnings Call Transcript

BioTime, Inc. (NYSEMKT:BTX) Q4 2018 Results Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants Ioana Hone - Investor Relations Brian Culley - Chief Executive Officer Brandi Robert - Chief Financial Officer Edward Wirth - CMO Gary Hogge - Senior Vice President of Clinical and Medical Affairs Conference Call Participants Naureen Quibria - Maxim Group Joseph Pantginis - H.C. Wainwright Reni Benjamin - Raymond James Keay Nakae - Chardan Operator Welcome to the BioTime, Inc. Fou...

376
Yahoo FinanceMar 14

BioTime: 4Q Earnings Snapshot

ALAMEDA, Calif. (AP) _ BioTime Inc. (BTX) on Thursday reported a loss of $45 million in its fourth quarter. The Alameda, California-based company said it had a loss of 35 cents per share. Losses, adjusted for non-recurring costs, came to 7 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 7 cents per share. Scroll to continue with content Ad The biotechnology company posted revenue of $758,000 in ...

432

Earnings

-$0.58
-$0.40
-$0.21
-$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.07 per share
Actual
-$0.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.